Ask AI
ProCE Banner Activity

A Call to Action: Enhancing Diagnostic Clarity and Treatment Navigation in Essential Thrombocythemia and Polycythemia Vera

Clinical Thought

Read this introductory commentary providing a brief overview of essential thrombocythemia and polycythemia vera management today. Then return to our program as we post new activities to learn in greater detail the latest evidence and recommendations for the personalized care of patients with essential thrombocythemia and polycythemia vera.

Released: January 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify and evaluate thrombotic presentations that may be indicative of underlying ET or PV.

  • Apply best practices in ET and PV diagnosis, including appropriate use of bone marrow biopsy and molecular testing for accurate subtype classification

  • Utilize prognostic scoring systems and immune biomarker data (e.g., Triple A model, MIPSS-ET, MIPSS-PV) to assess thrombotic risk and guide personalized treatment planning.

  • Implement shared decision-making strategies to align treatment goals with patient values, literacy levels, and logistical needs

  • Prepare to integrate emerging second-line therapies into clinical practice for patients with ET or PV who are intolerant or resistant to front-line therapy.

Disclosure

Primary Author

Andrew Kuykendall, MD: consultant/advisor/speaker: Bristol Myers Squibb, Geron, GSK, Incyte, Protagonist, Sobi, Takeda; researcher: Janssen, Kartos.